Preclinical studies show, that antibiotics disturbing gut bacteria reduce the effectiveness of immune therapies for cancers outside the gut (e. g. lung cancer or breast cancer). This is because antibiotics disturb the integrin signalling of immune cells in the intestine. As a result, overall trafficking of immune cells in the organism is disturbed and heavily influences immune responses in tumors distant to the intestine. In this project the scientists engineer integrin antibodies with the aim to restore healthy trafficking of immune cells in patients with disturbed gut microbiota prior to initiation of immunotherapy for cancer.

Here you can find further information.